Scott Andrew Smith
Summary
Scott Andrew Smith has served as Viatris’ Chief Executive Officer since April 1, 2023, after joining the company’s board in December 2022. ([viatris.com](https://www.viatris.com/en/about-us/executive-leadership-team/scott-smith?utm_source=openai))
Biography
Smith is a pharmaceutical and biotechnology executive with more than 35 years of industry experience. Before joining Viatris, he was president of BioAtla, where he helped build clinical-development capabilities, advance drug candidates into late-stage development and lead business-development activities. ([viatris.com](https://www.viatris.com/en/about-us/executive-leadership-team/scott-smith?utm_source=openai)) Earlier, Smith was president and chief operating officer of Celgene Corporation. He also held senior roles at Celgene, including senior vice president and global head of immunology and president of inflammation and immunology. Smith holds degrees in chemistry and biology and pharmacology and toxicology from Western University, plus an MBA from Thunderbird School of Global Management. ([viatris.com](https://www.viatris.com/en/about-us/executive-leadership-team/scott-smith?utm_source=openai))
Notable achievements
- Led Viatris through the completion of previously announced divestitures, including the over-the-counter business sale in July 2024. ([newsroom.viatris.com](https://newsroom.viatris.com/2024-07-03-Viatris-Brings-to-Completion-All-Previously-Announced-Divestitures-With-the-Closing-of-its-Over-the-Counter-Business-Divestiture?utm_source=openai))
- Oversaw a 2025 strategic review that the company said was intended to sharpen resource allocation and focus the portfolio on higher-quality growth. ([investor.viatris.com](https://investor.viatris.com/news-releases/news-release-details/viatris-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))
- Viatris reported meeting or exceeding its key 2025 financial guidance metrics under Smith’s leadership. ([investor.viatris.com](https://investor.viatris.com/news-releases/news-release-details/viatris-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))
- The company returned more than $1 billion to shareholders through dividends and share repurchases in 2025. ([investor.viatris.com](https://investor.viatris.com/news-releases/news-release-details/viatris-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))
Problem areas / controversies
- Viatris recorded a $2.9 billion goodwill impairment charge in 2025, reflecting a reduction in the carrying value of certain business assets. ([investor.viatris.com](https://investor.viatris.com/news-releases/news-release-details/viatris-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))
- An FDA warning letter issued in December 2024 cited quality-control and data-integrity concerns at the company’s Mylan Laboratories facility in India; the matter concerns Viatris operations rather than an allegation of personal misconduct by Smith. ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viatris-inc-690897-12192024?utm_source=openai))
- The company’s growth strategy remains an execution challenge: Viatris has described its strategic review and planned cost savings as steps toward future growth, rather than completed long-term results. ([investor.viatris.com](https://investor.viatris.com/news-releases/news-release-details/viatris-reports-fourth-quarter-and-full-year-2025-financial/?utm_source=openai))